Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 141 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Muscle tissue Biopsy Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers in Friedreich's Ataxia

NCT02497534
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
6 Years to 70 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Accelerating Post-exercise Muscle Glycogen Resynthesis in Humans: Impact of Combined Nutrient Intake and Intermittent Pneumatic Compression or Heat Therapy

NCT04371237
View directory record Official record
Conditions
Muscle Recovery, Muscle Soreness, Glycogen Depletion
Interventions
Compression sleeve, Heat therapy, Glycogen-depleting exercise session, Nutrient Intake (beverage), Skeletal muscle biopsy
Device · Other · Procedure
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 10, 2026, 2:32 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Electrical Stimulation of Human Myocytes in Microgravity

NCT03665051
View directory record Official record
Conditions
Sarcopenia
Interventions
Muscle Tissue Biopsy, Maximal Oxygen Consumption (V02max)
Procedure · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 10, 2026, 2:32 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082
View directory record Official record
Conditions
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cystoscopy, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab, Transurethral Resection of Bladder Tumor
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
381
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NCT07097142
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
211
States / cities
Fort Smith, Arkansas • Irvine, California • La Jolla, California + 162 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Early Phase 1 Interventional Results available

ICG and SLN Mapping

NCT05859971
View directory record Official record
Conditions
Breast Cancer
Interventions
SLN mapping using technetium-99m +/- isosulfan blue dye, SLN mapping with ICG fluorescence using the Asimov Platform
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 10, 2026, 2:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Determining Cell- and Spatially-distinct Skeletal Muscle Transcriptional Aberrations in Insulin Resistance

NCT07516509
View directory record Official record
Conditions
Insulin Resistance
Interventions
VO2 Max, DEXA, Peripheral Microvascular Reactivity, Skeletal Muscle Insulin Sensitivity, Non-Oxidative Glucose Disposal, Muscle tissue Biopsy
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
30 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Not yet recruiting Phase 4 Interventional

Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting

NCT07542314
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
ELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Enrolling by invitation No phase listed Observational

Physiologic and Functional Adaptations of Insulin Sensitive Tissues

NCT03407833
View directory record Official record
Conditions
Diabetes, Insulin Resistance, Obesity, Bariatric Surgery Candidate, Roux-en-y Gastric Bypass, Liver Diseases
Interventions
Endoscopy biopsy, Surgical biopsy, Mixed-meal tolerance test, Excised Liver Tissue Sampling
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 10, 2026, 2:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

NCT06839469
View directory record Official record
Conditions
Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Palo Alto, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Early Phase 1 Interventional

Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

NCT03473730
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC V8
Interventions
Biopsy, Daratumumab, Laboratory Biomarker Analysis, Metastasectomy, Nephrectomy
Procedure · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Not applicable Interventional

Project 4B: Lower Extremity Strength Training in ICU Patients

NCT02467023
View directory record Official record
Conditions
Sepsis
Interventions
Muscle stimulation with Niveus medical stimulator, measurement of maximal isometric twitch strength, Muscle Biopsy, Muscle Biopsy Medication: Lidocaine, Muscle Biopsy Medication: Versed, Muscle Biopsy Medication: Fentanyl, Blood and Urine Sampling, ineffective muscle stimulation
Device · Procedure · Drug + 1 more
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

NCT00777491
View directory record Official record
Conditions
Bladder Cancer
Interventions
induction cisplatin, induction 5-fluorouracil, induction gemcitabine, Induction BID radiation therapy, Induction QD radiation therapy, Consolidation BID radiation therapy, Consolidation QD radiation therapy, consolidation gemcitabine, consolidation 5-fluorouracil, consolidation cisplatin, radical cystectomy, Post-Induction Chemoradiotherapy Endoscopic Response Evaluation, adjuvant gemcitabine, adjuvant cisplatin
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
10
States / cities
Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome

NCT00006185
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Insulin Resistance
Interventions
Avandia administration for 6-12 weeks
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 10, 2026, 2:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting

NCT03121404
View directory record Official record
Conditions
Cirrhosis
Interventions
Rectus abdominis muscle biopsy
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

NCT05653258
View directory record Official record
Conditions
Obesity, Healthy Lifestyle
Interventions
Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg, Placebo, Abdominal adipose tissue biopsy
Other · Drug · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

NCT04917809
View directory record Official record
Conditions
Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
Interventions
Erdafitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Enhancing Adaptations to Exercise

NCT03350906
View directory record Official record
Conditions
Inflammation
Interventions
n3-PUFA, Placebo, Biopsy, Body Composition Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 10, 2026, 2:32 AM EDT
Active, not recruiting Not applicable Interventional

Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness

NCT00937001
View directory record Official record
Conditions
Myopathy, Cognitive Impairment
Interventions
Biopsy/Ultrasound
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
Russell Richardson
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 10, 2026, 2:32 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transcriptional and Epigenetic Program of PCOS Women

NCT04034706
View directory record Official record
Conditions
PCOS
Interventions
DEXA, Magnetic Resonance (MR) Assessment of the Abdomen, MR assessment of Whole Body Fat, Adipose tissue biopsy, Oral glucose tolerance test
Other · Procedure
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 10, 2026, 2:32 AM EDT
Active, not recruiting Phase 2 Interventional

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

NCT05821088
View directory record Official record
Conditions
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Carboplatin, Computed Tomography, Etoposide, Ifosfamide, Lenalidomide, Positron Emission Tomography, Tafasitamab
Procedure · Drug · Biological
Lead sponsor
David Bond, MD
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity

NCT04722354
View directory record Official record
Conditions
Pre Diabetes
Interventions
Hyperinsulemic euglycemic clamp, Muscle Biopsy, Oral abscisic acid (ABA), Placebo
Other · Procedure · Dietary Supplement
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 10, 2026, 2:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenomics of Thiazolidinediones

NCT01135394
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
35 Years to 64 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 10, 2026, 2:32 AM EDT